As both a global workplace and insulin producer and supplier, our key priorities during the COVID-19 pandemic is to safeguard the health of our employees and the continued supply of our medicines to people living with diabetes and other serious chronic diseases.
We are working closely with the UK government, health authorities and patient organisations to do what we can to improve the supply of healthcare equipment, research expertise and facilities, and information to help address concerns related to the availability of our medicines.
Clinical trial letter to patients - coming soon...
For more detailed information about Novo Nordisk's response to the COVID-19 pandemic, visit the dedicated section on our Global Site.
Date of last update: 26 March 2020